The intestinal microbiota has become a target for the treatment of inflammatory diseases both in the intestine and those of a systemic character. The development of therapeutic strategies directed at restoring the composition of the intestinal microbiota, such as through the administration of probiotics or prebiotics, could have a beneficial effect on metabolic syndrome.